European CHMP recommends approval of vericiguat (Verquvo) for treatment of chronic heart failure

This stimulator of soluble guanylate cyclase enzyme is indicated for treatment of chronic heart failure in adults with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy. It will be available as 2.5-mg, 5-mg and 10-mg tablets.

European Medicines Agency